<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="205873">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408603</url>
  </required_header>
  <id_info>
    <org_study_id>SPO-0010</org_study_id>
    <nct_id>NCT00408603</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer</brief_title>
  <official_title>A Phase 2 Open-Label, Multicenter Study of SNS-595 Injection in Patients With Platinum-Resistant Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunesis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunesis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the objective response rate, safety and identify
      potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin
      injection given on a 28-day cycle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Other objectives of this study are to evaluate Progression-free survival and measure CA-125
      response rate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response rate</measure>
    <time_frame>Prior to Cycles 3, 5, 7, etc...</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Each cycle</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>For all patients with stable disease or better every 3 months after end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of potential biomarkers</measure>
    <time_frame>Each cycle</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>All study patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive voreloxin injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voreloxin Injection</intervention_name>
    <description>All patients will receive voreloxin injection.</description>
    <arm_group_label>All study patients</arm_group_label>
    <other_name>SNS-595</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically documented epithelial ovarian cancer, primary
             peritoneal carcinoma, or fallopian tube cancer

          -  Completed at least one Platinum Based Therapy (PBT) regimen (carboplatin, cisplatin,
             or another organoplatinum compound).

          -  Evidence of platinum-resistant disease, relapse/progression within 6 months of the
             completion of PBT, or intolerant to PBT (inability to receive PBT due to
             hypersensitivity reactions to platinum)

          -  Patients with primary platinum-resistant disease are allowed to receive no more than
             one nonplatinum cytotoxic regimen and no more than one noncytotoxic regimen for the
             management of recurrent or persistent disease after the development of primary
             platinum-resistance.

          -  Measurable disease per GOG-RECIST criteria

          -  GOG Performance Status of 0 or 1

        Exclusion Criteria:

          -  Radiotherapy, chemotherapy, and hormonal, cytokine, or targeted therapy, within 3
             weeks (nitrosurea or mitomycin C within 6 weeks) prior to the anticipated first day
             of treatment.

          -  Monoclonal antibody therapy within 4 weeks prior to clinical study entry

          -  Unresolved or impending bowel obstruction

          -  Other active malignancies or other malignancies within the last 12 months except
             nonmelanoma skin cancer or cervical intraepithelial neoplasia

          -  Prior radiotherapy to more than 25% of the marrow space

          -  Requiring hemodialysis or peritoneal dialysis

          -  Myocardial infarction or cerebrovascular accident/transient ischemic attack within
             the 6 months prior to the anticipated first day of treatment

          -  Thromboembolic event (deep vein thrombosis [DVT] or pulmonary embolus [PE]) within 28
             days prior to the anticipated first day of treatment

          -  History of active CNS metastases

          -  Any other medical, psychological, or social condition that would contraindicate the
             patient's participation in the clinical study due to safety or compliance with
             clinical study procedures.

        Please note: There are additional inclusion/exclusion criteria for this study. Please
        contact the study center for additional information and to determine if you meet all study
        criteria.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunesis Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunesis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Oncology of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynecologic Oncology Associates</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Clinical Oncology Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Research Institute at Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, S.C. at Luthern General Advanced Care Center</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Oncology Clinical Research Program</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Harry and Jeanette Weinberg Institute at Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (MSKCC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente NW Region</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center at Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hall and Martin, MD's, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency at Centre for Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency at Fraser Valley Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency at Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency - Vancouver Island Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre Department of Oncology</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <lastchanged_date>June 5, 2012</lastchanged_date>
  <firstreceived_date>December 5, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>second line treatment</keyword>
  <keyword>platinum resistant</keyword>
  <keyword>ovary</keyword>
  <keyword>ovaries</keyword>
  <keyword>cancer</keyword>
  <keyword>epithelial</keyword>
  <keyword>carcinomas</keyword>
  <keyword>tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
